Embecta Corp. (NASDAQ:EMBC) to Issue $0.15 Quarterly Dividend

Embecta Corp. (NASDAQ:EMBC) announced a quarterly dividend on Thursday, February 5th. Investors of record on Friday, February 27th will be given a dividend of 0.15 per share on Tuesday, March 17th. This represents a c) annualized dividend and a yield of 5.7%. The ex-dividend date is Friday, February 27th.

Embecta has a payout ratio of 21.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Embecta to earn $3.07 per share next year, which means the company should continue to be able to cover its $0.60 annual dividend with an expected future payout ratio of 19.5%.

Embecta Trading Down 7.8%

EMBC traded down $0.88 on Thursday, reaching $10.47. The company had a trading volume of 1,649,586 shares, compared to its average volume of 636,609. The company has a market capitalization of $619.93 million, a P/E ratio of 6.42 and a beta of 1.11. The company has a fifty day moving average of $11.80 and a 200-day moving average of $12.95. Embecta has a one year low of $9.20 and a one year high of $18.12.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.04. The company had revenue of $261.20 million during the quarter, compared to analyst estimates of $258.07 million. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The business’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.65 EPS. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Research analysts predict that Embecta will post 2.85 EPS for the current year.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.